HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Inverness JV results: The first product from Inverness Medical Innovations' consumer diagnostic joint-venture with Procter & Gamble is expected to launch in the U.S. late this year following an international launch, Inverness announces during its fiscal 2007 fourth-quarter earnings call Feb. 20. In May 2007 the firms completed a joint venture to create SPD Swiss Precision Diagnostics, a business that develops, manufactures and markets diagnostic products including pregnancy tests and fertility/ovulation monitoring products (1"The Tan Sheet" Jan. 1, 2007, p. 10). During the October-December period, responsibility for U.S. sales and distribution of SPD's products was transitioned from Inverness to P&G. Inverness' consumer diagnostics business achieved sales of $29.7 million in the quarter, compared to $42.2 million in the prior-year quarter as the firm incurred $16.1 million in costs linked to the joint venture...

You may also be interested in...



Sales & Earnings In Brief

Herbalife's "soft" spot: Multilevel nutritional supplement marketer Herbalife reaches record annual net sales of $2.4 billion for 2008 despite an 11.3 percent drop in fourth-quarter net sales to $512.9 million. "Unprecedented currency fluctuations" cut into fourth-quarter income, reducing net sales by 856 basis points and causing a 2.7 percent drop in local currency year-over-year sales, the Los Angeles-based company says Feb. 24. "We ended the year on a soft note," Chairman and CEO Michael Johnson said. The company in December began restructuring to lower costs by improving alignment with its distributors and reducing workload. For the October-December period, the company's net income fell 59.6 percent to $33.7 million, due in part to general and administration expenses and lower sales. Fourth-quarter sales were down in each of the firm's regions other than a flat performance in North America, $109.3 million. Sales dropped 18.9 percent in Europe, the Middle East and Africa region to $117.4 million, 4.5 percent in Asia Pacific to $97 million, 20.7 percent in South America to $78.8 million and 28.5 percent in Mexico and Central America to $69.9 million, Herbalife said. Full-year sales grew 9.9 percent and net income grew 13.4 percent to $221.2 million, or $3.36 per diluted share. Herbalife added 45,657 sales associates in the quarter, 19.5 percent fewer than the year-ago period, but the number increased 6.6 percent for the year to 505,094

Inverness Forced To Release Pregnancy Test Technology

Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission

P&G Moves Into Consumer Diagnostics With Inverness Joint Venture

Procter & Gamble enters the consumer diagnostic products business with an agreement to form a 50/50 joint venture with Waltham, Mass.-based Inverness Medical Innovations

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel